Q-omics provides the consensus-scored GTF2H3 profile across patient tissues and cancer cell-line models. GTF2H3 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, GTF2H3 is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, GTF2H3 RNA expression shows 19,764 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight MESO, HNSC, and ACC as cancer lineages where GTF2H3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GTF2H3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GTF2H3 survival associations across molecular data types. GTF2H3 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (3) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GTF2H3 RNA expression–survival associations across cancer types. High GTF2H3 expression shows unfavorable associations in MESO, LIHC, UVM and ACC, but favorable associations in KIRC and BRCA. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify MESO as the clearest survival context for GTF2H3 RNA expression.
This table summarizes GTF2H3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for GTF2H3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GTF2H3 shows higher tumor expression in HNSC, LIHC, STAD, BLCA, KIRP and LUSC. The HNSC box plot shows higher GTF2H3 RNA expression in tumor versus normal tissue (log2 FC = +0.894, t-test p < 0.001).
This table shows molecular features associated with GTF2H3 in patient tissues and cancer cell lines. In patient samples, GTF2H3 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, GTF2H3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and UPPER_AERODIGESTIVE_TRACT.
